Materials Modelling and Modal Analysis of the Lighthouse in the Venetian Harbour of Chania

  &nbsp

Short- and long-term effects of amoxicillin/clavulanic acid or doxycycline on the gastrointestinal microbiome of growing cats

Antibiotic treatment in early life influences gastrointestinal (GI) microbial composition and function. In humans, the resultant intestinal dysbiosis is associated with an increased risk for certain diseases later in life. The objective of this study was to determine the temporal effects of antibiotic treatment on the GI microbiome of young cats. Fecal samples were collected from cats randomly allocated to receive either amoxicillin/clavulanic acid (20 mg/kg q12h) for 20 days (AMC group; 15 cats) or doxycycline (10 mg/kg q24h) for 28 days (DOX group;15 cats) as part of the standard treatment of upper respiratory tract infection. In addition, feces were collected from healthy control cats (CON group;15 cats). All cats were approximately two months of age at enrolment. Samples were collected on days 0 (baseline), 20 or 28 (AMC and DOX, respectively; last day of treatment), 60, 120, and 300. DNA was extracted and sequencing of the 16S rRNA gene and qPCR assays were performed. Fecal microbial composition was different on the last day of treatment for AMC cats, and 1 month after the end of antibiotic treatment for DOX cats, compared to CON cats. Species richness was significantly greater in DOX cats compared to CON cats on the last day of treatment. Abundance of Enterobacteriales was increased, and that of Erysipelotrichi was decreased in cats of the AMC group on the last day of treatment compared to CON cats. The abundance of the phylum Proteobacteria was increased in cats of the DOX group on days 60 and 120 compared to cats of the CON group. Only minor differences in abundances between the treatment groups and the control group were present on day 300. Both antibiotics appear to delay the developmental progression of the microbiome, and this effect is more profound during treatment with amoxicillin/clavulanic acid and one month after treatment with doxycycline. Future studies are required to determine if these changes influence microbiome function and whether they have possible effects on disease susceptibility in cats.S1 Fig. Beta diversity indices among groups. A) Principal Coordinate Analysis of unweighted UniFrac distances of 16S rRNA genes representing the difference in microbial communities among cats treated with amoxicillin clavulanic acid (blue circles), cats treated with doxycycline (yellow circles), and healthy control cats (red circles) on days 20/28 (last day of treatment), 60, 120, and 300. B) Principal Coordinate Analysis of weighted UniFrac distances of 16S rRNA genes representing the difference in microbial communities among cats treated with amoxicillin clavulanic acid (blue circles), cats treated with doxycycline (yellow circles), and healthy control cats (red circles) on days 20/28 (last day of treatment), 60, 120, and 300.S2 Fig. Rarefaction curves for A) Chao1, B) Observed ASVs, and C) Shannon Index.S1 Table. Clinical data of cats participating to the study.S2 Table. Alpha diversity metrics (mean ± standard deviation) with summary statistics; CON, healthy cats that did not receive antibiotics; AMC, cats treated with amoxicillin/clavulanic acid for 20 days; DOX, cats treated with doxycycline for 28 days.S3 Table. Beta diversity differences based on ANOSIM analysis. CON, healthy cats that did not receive antibiotics; AMC, cats treated with amoxicillin/clavulanic acid for 20 days; DOX, cats treated with doxycycline for 28 days.S4 Table. Beta diversity differences based on PERMANOVA analysis. CON, healthy cats that did not receive antibiotics; AMC, cats treated with amoxicillin/clavulanic acid for 20 days; DOX, cats treated with doxycycline for 28 days.S5 Table. Summary statistics of sequencing data describing the mean percent and standard deviation of sequences belonging to antibiotic-treated (AMC and DOX groups) and healthy (CON group) cats.S6 Table. Summary statistics of qPCR data describing the mean log abundance and standard deviation of bacterial groups belonging to antibiotic-treated (AMC and DOX groups) and healthy (CON group) cats.The Miller Trust Award of the Winn Feline Foundation.http://www.plosone.orgam2022Production Animal Studie

Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients

BACKGROUND: Fabry disease (FD, OMIM 301500) is an X-linked inborn error of glycosphingolipid metabolism due to the deficient activity of alpha-galactosidase A, a lysosomal enzyme. While the progressive systemic deposition of uncleaved glycosphingolipids throughout the body is known to have protean clinical manifestations, few data are available regarding the cochlear involvement. METHODS: We non-invasively investigated cochlear functions in 22 consecutive hemizygous males (age 19–64 years, mean 39) affected with classic FD. Conventional audiometry, tympanometry, ABR audiometry, otoacoustic emissions were performed in all patients, together with medical history record and physical examination as part of an exhaustive baseline evaluation prior to enzyme replacement therapy. RESULTS: A total of 12 patients (54.5%) with classic FD were found to have abnormal audition. Five patients had progressive hearing loss and seven patients (32%) experienced sudden deafness. In addition, a hearing loss on high-tone frequencies was found in 7 out of the 10 remaining patients without clinical impairment, despite their young age at time of examination. The incidence of hearing loss appeared significantly increased in FD patients with kidney failure (P < 0.01) or cerebrovascular lesions (P < 0.01), whereas there was no correlation with left ventricular hypertrophy. In addition, tinnitus aurium was also found in six patients (27%). CONCLUSION: This is the first evidence of a high incidence of both progressive hearing loss and sudden deafness in a cohort of male patients affected with classic Fabry disease. The exact pathophysiologic mechanism(s) of the cochlear involvement deserves further studies

Validation platform implementation description - D5.2

This deliverable describes different test-beds for the validation of the architecture, algorithms and protocols for the operator governed opportunistic networking as defined in the OneFIT Project. Further on, this deliverable provides a description of the implementation of the OneFIT cognitive management systems CSCI and CMON as well as the C4MS protocol. Also, implementation of the blocks supporting the OneFIT system (JRRM, CCM, DSONPM, and DSM) is described. This document also describes the implementation of the OneFIT scenarios for opportunistic coverage extension, opportunistic capacity extension, infrastructure supported ad-hoc networking and device-to-device communication as well as opportunistic resource aggregation in the backhaul network

Results analysis and validation - D5.3

This deliverable describes the validation processes followed to assess the performance of the algorithms and protocols for the operator governed opportunistic networking as defined in the OneFIT Project. Therefore, this document includes the description of the set-up of the different validation platforms, the design of the test plans for each one of them, and the analysis of the results obtained from the tests. A per-scenario approach rather than a per-platform approach has been followed, so an additional analysis has been performed, gathering the results related to each scenario, in order to validate the premises stated to each one of them. The OneFIT concept has been therefore validated for all foreseen business scenarios

Unilateral contact applications using FEM software

International audienceNonsmooth analysis, inequality constrained optimization and variational inequalities are involved in the modelling of unilateral contact problems. The corresponding theoretical and algorithmic tools, which are part of the area known as nonsmooth mechanics, are by no means classical. In general purpose software some of these tools (perhaps in a simplified way) are currently available. Two engineering applications, a rubber-coated roller contact problem and a masonry wall, solved with MARC, are briefly presented, together with elements of the underlying theory

Modified supracricoid partial laryngectomy with cricohyoidopexy: Series report and analysis of results

Aiming to improve voice quality and to facilitate swallowing rehabilitation, we modified the supra-cricoid partial laryngectomy with cricohyoidopexy by preserving the posterior segment of the true vocal cord on the less involved side of the larynx. Between 1983 and 1994, 13 patients with supraglottic cancer were treated with this modified procedure. The possibility of incomplete tumor excision was eliminated by careful patient selection and intraoperative reconfirmation of tumor extent with frozen sections. Our results have been promising, with a 76.9% 3-year survival rate and a 69.2% laryngeal preservation rate. There were 7 recurrences, 3 local (2 at the superior border of the cricoid and 1 at the cricoarytenoid region) and 4 nodal, in 5 patients. Distant metastases developed in another patient. Three patients, 2 with local and nodal recurrence and 1 with distant metastases, died of disease. Functional outcomes were also good, with all patients achieving normal swallowing by the end of the first year, although 5 patients required temporary gastrostomy for transient swallowing impairment, Early decannulation and satisfactory voice quality were achieved in all cases, We believe that with proper patient selection this modified procedure is effective both for tumor control and for preserving a more functional larynx

Drug Delivery Through Multifunctional Polypeptidic

Over the last two decades, remarkable progress has been made to the discovery of novel drugs as well as their delivery systems for the treatment of cancer, the major challenge in medicine. Pharmaceutical scientists are trying to shift from traditional to novel drug delivery systems by applying nanotechnology and, in particular, polymeric carriers to medicine. In complex diseases, very sophisticated nanocarriers should be designed to encapsulate a significant quantity of drugs and bypass biological barriers with minimum cargo loss to effectively and directly deliver the encapsulated drug to the desired pathological site. One of the most promising classes of polymeric materials for drug delivery applications is polypeptides, combining the properties of the traditional polymers with the 3D structure of natural proteins, i.e., a-helices and β-sheets. In this chapter, we present the recent progress in the synthesis of polymers that form hydrogels in aqueous solutions, based on polypeptides prepared through ring-opening polymerization of N-carboxy anhydrides and which have been loaded with anticancer drugs and studied for their functionality. Advancements in drug design and improvement of multifunctional nanocarriers from the combination of well-defined macromolecular architectures and smart materials are the future for the successful treatment of numerous lethal diseases. © 2021, Springer Science+Business Media, LLC, part of Springer Nature